November 2005

Yeast Surface Display of a Noncovalent MHC Class II Heterodimer Complexed with Antigenic Peptide

Eric T. Boder

University of Pennsylvania, boder@seas.upenn.edu

Jerome R. Bill

University of Colorado Health Sciences Center

Andrew W. Nields

University of Pennsylvania

Philippa C. Marrack

University of Colorado Health Sciences Center

John W. Kappler

University of Colorado Health Sciences Center

Follow this and additional works at: https://repository.upenn.edu/cbe_papers

Recommended Citation

Boder, E. T., Bill, J. R., Nields, A. W., Marrack, P. C., & Kappler, J. W. (2005). Yeast Surface Display of a Noncovalent MHC Class II Heterodimer Complexed with Antigenic Peptide. Retrieved from https://repository.upenn.edu/cbe_papers/61

Postprint version. "This is a preprint of an article published in *Biotechnology and Bioengineering*, Volume 92, Issue 4, November 20, 2005, pages 485-491."

Publisher URL: <http://dx.doi.org/10.1002/bit.20616>

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/cbe_papers/61

For more information, please contact repository@pobox.upenn.edu.

Yeast Surface Display of a Noncovalent MHC Class II Heterodimer Complexed with Antigenic Peptide

Abstract

Microbial protein display technologies have enabled directed molecular evolution of binding and stability properties in numerous protein systems. In particular, dramatic improvements to antibody binding affinity and kinetics have been accomplished using these tools in recent years. Examples of successful application of display technologies to other immunological proteins have been limited to date. Herein, we describe the expression of human class II major histocompatibility complex allele (MHCII) HLA-DR4 on the surface of *Saccharomyces cerevisiae* as a noncovalently associated heterodimer. The yeast-displayed MHCII is fully native as assessed by binding of conformationally specific monoclonal antibodies; failure of antibodies specific for empty HLA-DR4 to bind yeast-displayed protein indicates antigenic peptide is bound. This report represents the first example of a noncovalent protein dimer displayed on yeast and of successful display of wildtype MHCII. Results further point to the potential for using yeast surface display for engineering and analyzing the antigen binding properties of MHCII.

Keywords

yeast display, class II MHC, peptide loading, heterodimer expression in yeast, protein engineering

Comments

Postprint version. "This is a preprint of an article published in *Biotechnology and Bioengineering*, Volume 92, Issue 4, November 20, 2005, pages 485-491."

Publisher URL: <http://dx.doi.org/10.1002/bit.20616>

Yeast Surface Display of a Noncovalent MHC Class II Heterodimer Complexed with Antigenic Peptide

Eric T. Boder^{1,2,3*}, Jerome R. Bill^{4,5,8}, Andrew W. Nields^{1,3},

Philippa C. Marrack^{4,6,8,9}, and John W. Kappler^{4,7,8,9}

¹Department of Chemical & Biomolecular Engineering, ²Department of Bioengineering,
³Institute for Medicine and Engineering, University of Pennsylvania, Philadelphia, PA 19104;
⁴Integrated Department of Immunology, ⁵Department of Medicine, ⁶Department of Biochemistry
and Molecular Genetics, ⁷Department of Pharmacology and Program in Biomolecular Structure,
University of Colorado Health Sciences Center, Denver, CO 80262; ⁸Integrated Department of
Immunology, ⁹Howard Hughes Medical Institute, National Jewish Medical and Research Center,
Denver, CO 80206.

* Corresponding author: Dr. Eric T. Boder, Department of Chemical and Biomolecular
Engineering, University of Pennsylvania, 220 South 33rd Street, Philadelphia, PA 19104.
Tel: (215) 898-5658, Fax: (215) 573-2093; Email: boder@seas.upenn.edu

ABSTRACT

Microbial protein display technologies have enabled directed molecular evolution of binding and stability properties in numerous protein systems. In particular, dramatic improvements to antibody binding affinity and kinetics **have** been accomplished using these tools in recent years. Examples of successful application of display technologies to other immunological proteins have been limited to date. Herein, we describe the expression of human class II major histocompatibility complex allele (MHCII) HLA-DR4 on the surface of *Saccharomyces cerevisiae* as a noncovalently associated heterodimer. The yeast-displayed MHCII is fully native as assessed by binding of conformationally specific monoclonal antibodies; failure of antibodies specific for empty HLA-DR4 to bind yeast-displayed protein indicates antigenic peptide is bound. This report represents the first example of a noncovalent protein dimer displayed on yeast and of successful display of wild-type MHCII. **Results further point to the potential for using yeast surface display for engineering and analyzing the antigen binding properties of MHCII.**

Keywords: yeast display, class II MHC, peptide loading, heterodimer expression in yeast, protein engineering

INTRODUCTION

Class II MHC are membrane proteins expressed primarily on the surface of professional antigen presenting cells (APC; e.g., macrophages, dendritic cells, and B cells) and consist of two noncovalently associated chains, α and β (Stern and Wiley 1994). Each of these chains contains two domains. The peptide antigen binding site is formed from the $\alpha 1$ and $\beta 1$ domains, while the Ig-like $\alpha 2$ and $\beta 2$ domains likely aid folding and association in the endoplasmic reticulum. CD4+ $\alpha\beta$ T lymphocytes respond to antigen peptides only when bound to MHCII presented on the surface of APC.

MHCII bound to defined antigenic peptides have been produced using a polypeptide linker attaching the peptide to the β chain N-terminus (Kozono et al. 1994). Tetramerization of these molecules by site-specific biotinylation (Cull and Schatz 2000) and avidin binding has enabled dramatic progress in the study of T cell-mediated immune phenomena (Altman et al. 1996; Kotzin et al. 2000). Specifically, tracking of antigen-specific T cells **during active immune responses in vivo** has been become possible (Reijonen and Kwok 2003; Skinner et al. 2000), as well as screening of putative peptide antigens against T cells to identify reactive peptides (Novak et al. 2001). Engineered, MHC-based reagents have also shown promise in inhibition of T cell-mediated autoimmune disease (Huan et al. 2004). Consequently, methods to engineer molecular properties of these important molecules would be of great value.

The utility of directed evolution and display technologies for protein engineering **[reviewed by (Chen and Georgiou 2002; Hoogenboom 2002; Pluckthun et al. 2000)]** has been well established in a number of systems including antibodies, enzymes, protease inhibitors, novel binding domains, cytokines, and mammalian cell surface receptor proteins. However,

application of this methodology to T cell receptors (TCR) and major histocompatibility complex proteins (MHC), critical surface proteins involved in T cell mediated immune responses, have been few (Chlewicki et al. 2005; Esteban and Zhao 2004; Holler et al. 2003; Holler et al. 2000; Kieke et al. 1999; Shusta et al. 2000; Weidanz et al. 1998). Phage display of MHC has proved to be particularly challenging, and only three examples of successful display of class I MHC have been demonstrated to date (Kurokawa et al. 2002; Le Doussal et al. 2000; Vest Hansen et al. 2001). The lack of MHC phage display data is unsurprising as these proteins are natively heterodimeric with intrachain disulfide bonds; furthermore, at least some MHC proteins demonstrate poor stability or nonnative conformations in the absence of bound antigen peptide (Arimilli et al. 1999; Germain and Rinker 1993). These issues complicate heterologous expression in prokaryotic hosts, which is a prerequisite for phage display.

In contrast to phage display, yeast surface display relies upon a eukaryotic host for expression of the gene of interest while maintaining the genotype-phenotype linkage requisite for directed molecular evolution. The method has been validated by successful studies applied to numerous single-chain antibodies (Wittrup 2001), antibody Fab fragments (Lin et al. 2003; Weaver-Feldhaus et al. 2004), and a single-chain T cell receptor (Holler et al. 2000; Kieke et al. 1999; Shusta et al. 2000). Yeast's ability to perform many of the post-translational modifications typical of secreted mammalian proteins represents a decided advantage of this technology. Three recent studies have demonstrated the ability of yeast to surface display both class I and class II MHC (Brophy et al. 2003; Esteban and Zhao 2004; Starwalt et al. 2003). A single-chain derivative of an MHCI was successfully displayed, and putatively functional as judged by direct, antigen-specific T cell activation using yeast as the antigen presenting particle (Brophy et al. 2003). However, the yeast-displayed MHCI in this study (murine H-2K^b) was also expressed by

the T cells assayed, and the experiments performed were unable to rule out peptide transfer and T cell autostimulation as the activation mechanism (Ge et al. 2002). In an elegant study, Kranz and coworkers isolated thermodynamically stabilized mutants of **single-chain murine MHCII I-A^{g7}** via screening of combinatorial libraries and demonstrated the importance of two polymorphic β chain positions in this stabilization (Starwalt et al. 2003). These yeast-displayed MHCII failed to demonstrate peptide binding or T cell activation. Likewise, directed evolution was recently applied to engineer yeast-displayable mutants of a single-chain derivative of HLA-DR1, although data regarding T cell receptor reactivity was not presented (Esteban and Zhao 2004). **Most significantly, protein mutations were required to achieve expression of DR1 in this system; thus, structure-function studies using this displayed protein must be approached cautiously as the mutant protein properties may not be representative of wild-type HLA-DR1.**

Recently, surface display of Fab antibody fragments on yeast was demonstrated. An anti-streptavidin antibody heavy chain was expressed as a fusion to the C-terminus of the yeast Aga2p mating agglutinin (van den Beucken et al. 2003); the light chain was expressed from a separate promoter and the heterodimer was stabilized through the Fab interchain disulfide bond. A similar expression system for Fab libraries with free N-termini has also recently been demonstrated (Weaver-Feldhaus et al. 2004), as has yeast display of a catalytic Fab (Lin et al. 2003). These studies represent the first examples of assembly and display of multimeric proteins on yeast without the aid of a single-chain linker. In this work, we further establish the ability of the yeast surface display system to correctly assemble and display a heterodimer in which interchain interactions are entirely noncovalent. **Significantly, our results represent the first example of yeast display of wild-type MHCII and therefore represent an important advance toward the ability to analyze and engineer MHCII-peptide interactions in the absence of**

potentially confounding MHCII mutations. Yeast displayed HLA-DR4 demonstrates peptide binding activity; however, our data indicate that yeast are incapable of stimulating antigen-specific T cells and thus suggest that engineering and analysis of MHCII by yeast display is limited to peptide-binding and structural stability applications.

MATERIALS AND METHODS

Yeast expression vectors

Expression vectors for yeast display of DR4 were based upon previously described plasmid pCT302 (Boder et al. 2000). A PCR fragment of the extracellular domain of HLA-DRB1*0401 (amino acids 30 – 223) with N-terminal HA (307 – 319) peptide and thrombin-cleavable linker (Kozono et al. 1994) was cloned into pCT302 via primer-encoded Nhe I and Xho I restriction sites. This created an in-frame fusion C-terminal to the AGA2 gene (plasmid pCT-DR4 β). A dual cassette expression vector was created by cloning the yeast mating factor α 1 transcriptional terminator sequence 5' of the yeast GAL1-10 bidirectional promoter, enabling galactose-inducible co-expression of two open reading frames from one plasmid. A PCR fragment of the extracellular domain of HLA-DRA1*0101 with a synthetic PRE-PRO signal sequence (Arnold et al. 1998) was cloned into plasmid pCT-DR4 β 5' of the GAL1-10 promoter (i.e., downstream of the GAL10 promoter) to create plasmid Z27.

Plasmid Z47 (Figure 1) was constructed similarly by cloning a FLU-DR4 β extracellular domain PCR product pCT4-scFv. The resulting FLU-DR4 β -AGA2 cassette (AGA2 beginning with residue 20) was subcloned to place it behind the GAL10 promoter and in frame with a synthetic PRE-PRO leader sequence.

Expression and purification of soluble HLA-DR4

A baculovirus shuttle vector containing p10 and polyhedrin promoters driving expression of HLA-DR4 β with covalent FLU peptide and HLA-DR α extracellular domains was used to cotransfect Sf9 cells along with BaculoGold baculovirus DNA (Pharmingen) according to the manufacturer's instructions. Viral stocks were isolated after 10 days and amplified once by infection of Sf9 cells and culturing for 7 days. The resulting high titer stocks were used to infect suspension-adapted High Five (Invitrogen) cells at 2×10^6 cells/mL. Protein was produced by spinner flask culture for 6 days at 27°C in TMN/FH medium plus 10% Pluronic F-68. Assembled HLA-DR4-FLU heterodimers were purified from culture supernatants by affinity chromatography. Anti-DR α mAb LB3.1 was produced from hybridoma culture, purified by protein A-Sepharose affinity chromatography (Pharmacia), and coupled to activated CNBr-Sepharose.

Following affinity chromatography, monomeric DR α chain was removed by size exclusion chromatography (Pharmacia FPLC, Superdex 10/200). Heterodimer identity was confirmed by reducing and non-reducing SDS-PAGE electrophoresis and Coomassie staining. DR4-FLU protein was concentrated to ~4 mg/mL and enzymatically biotinylated as described (Crawford et al. 1998). Free biotin was removed by FPLC, and biotin incorporation was confirmed by avidin-agarose depletion and quantitative ELISA using anti-DR4 β mAb L227 and biotinylated anti-DR α mAb LB3.1.

Immunofluorescent staining and flow cytometry

3 mL of SD-CAA (Boder et al. 2000) were inoculated with a single yeast colony and grown overnight at 30° to an OD₆₀₀ of 2.0 – 5.0. 3×10^7 cells were collected, switched to 3 mL SG-CAA (galactose replaces glucose) + 10% glycerol, grown 24 hrs at 30°C, then stored at 4°C. 1.6×10^7 cells were collected, spun, resuspended in 1 mL PBSB (137 mM NaCl, 2.7 mM KCl,

10.1 mM Na₂HPO₄, 1.8 mM KH₂PO₄, 1% (w/v) BSA, pH 7.4), spun again, resuspended in 0.4 mL PBSB, and incubated at 80°C for 1 hr. A control group was kept at 4°C. After the 80°C incubation, both sets of cells were washed twice with 1 mL PBSB and resuspended in 0.8 mL PBSB. 100 μ L aliquots of these suspensions ($\sim 2 \times 10^6$ cells) were individually centrifuged and resuspended in 100 μ L PBSB containing 1° Ab: 9E10 (Covance, 1:100), bio-12CA5 (Roche, 1:20), L243 (BD Pharmingen, 2:5), LB3.1 (22 μ g/mL), L227 (15 μ g/mL), KL295 (15 μ g/mL), or KL304 (15 μ g/mL). The samples were then added to a 96-well plate and incubated on ice for 45 min. The plate was washed three times by centrifuging at 3000g for 5 min and adding 200 μ L PBSB to each well. After washing, 100 μ L of PBSB containing 2° Ab (goat anti-mouse-PE, Sigma, 1:20) was added to each well, and the plate was incubated on ice for 45 min. After washing, the cells were analyzed on a BD FACScan flow cytometer.

T cell activation assays

75IP fibroblasts transfected with HLA-DR4 (Boen et al. 2000) were cultured in D-MEM (LTI) + 10% FCS. FLU-specific and HLA-DR4-restricted T cell hybridoma HA1.7 (Lamb et al. 1982) were cultured in complete tumor media (CTM) (Kappler et al. 1981). To test for T cell activation, stimulating particles (10^5 for fibroblasts, or $2 \times 10^5 - 1 \times 10^6$ for yeast or antigen-coated beads) were added to a 96-well plate to a final volume of 250 μ L. 75IP-DR4-FLU positive controls elicited >1200 U/mL IL-2 in all experiments. In some experiments, yeast were lethally UV irradiated prior to the assay using a Stratalinker UV crosslinking apparatus (Stratagene) at ~ 1 J/cm² for 3 mins. This prevented overgrowth of the culture during the overnight stimulation assay. Following incubation for 24 hrs at 37°C in 5% CO₂, medium supernatants were isolated and IL-2 levels were assayed by the HT-2 bioassay (Kappler et al.

1981). Wells containing live HT-2 cells were identified by light microscopy following overnight incubation in serially diluted activation supernatants.

RESULTS

Yeast expression of HLA-DR4flu

Yeast display of proteins has been commonly accomplished by recombinant expression of the protein of interest fused to the Aga2p subunit of **a**-agglutinin, a cell wall protein involved in cell-cell adhesion during mating (Shen et al. 2001). Two constructs were developed to test surface expression of human MHCII HLA-DR4 in yeast (Figure 1). Both constructs attached the Aga2p fusion partner to a covalent peptide-MHCII β chain construct via an intervening (Gly₄-Ser)₃ linker sequence. The influenza hemagglutinin 307 – 319 peptide (FLU) was attached to DR4 β through a previously described flexible linker segment (Kozono et al. 1994). One fusion (construct A) incorporated Aga2p at the N-terminus of the **FLU-DR4 β** protein, a format similar to that used in prior yeast display studies (Boder and Wittrup 2000). N-terminal extensions appended to covalently associated peptides have been previously shown to affect the conformation of MHCII (Rotzschke et al. 1999); thus, a second construct with the Aga2p fusion partner linked to the **C-terminus of FLU-DR4 β** was designed. In both cases, the DR α chain was expressed as a soluble protein from a separate cassette making use of the bidirectional GAL1-10 promoter, as shown in Figure 1. Heterodimeric protein expression on the yeast surface was assessed by immunofluorescent staining. **As shown in Figures 2 and 3(B)**, mAb specific for both the α (L243 and LB3.1) and β (L227) chains of DR4 recognize the yeast-displayed protein. Furthermore, binding of both L243 and LB3.1 is sensitive to native conformation **and heterodimeric assembly** of HLA-DR molecules (Horejsi et al. 1986). These data therefore indicate that yeast-displayed HLA-DR4 is assembled as a native heterodimer. Yeast expressing

construct A exhibit little reactivity with L227 and substantially lower reactivity with L243 and LB3.1 in comparison to construct B; thus, linkage of the Aga2p fusion partner at the C-terminus of MHCII β appears to be necessary for efficient expression in this context.

Peptide loading status of yeast-displayed HLA-DR4

To confirm that peptides were indeed loaded in the antigen-binding groove of yeast displayed HLA-DR4, additional immunofluorescence studies were performed. Monoclonal antibodies KL295 and KL304 (LaPan et al. 1992) recognize denatured HLA-DR1 and HLA-DR4 by binding to a sequence in the helical region of the β 1 domain (Zarutskie et al. 1999). A significant increase in cell staining by KL295 and KL304 was observed upon heat denaturation of yeast at 80°C (Figure 3). Likewise, complete loss of L243 and LB3.1 epitopes on HLA-DR α was observed in these studies, while staining for the HA epitope tag at the C-terminus of the DR4 β -Aga2p fusion remained unchanged. Taken together, these results indicate that yeast-displayed HLA-DR4 is fully native and peptide-loaded.

Failure of T cell stimulation

Despite displaying native HLA-DR4, yeast proved unable to stimulate IL-2 production by FLU-specific and HLA-DR4-restricted T cell hybridoma HA1.7 (data not shown). To ascertain the ability of yeast to engage in requisite intercellular interactions with T cells, yeast were coated with HLA-DR4-FLU protein produced by baculovirus-infected insect cells (bvDR4). Randomly biotinylated yeast were incubated with ExtrAvidin™ at high concentration to yield immobilized protein with unoccupied biotin binding sites. Avidin-coated yeast were then incubated with bvDR4 enzymatically biotinylated via a c-terminal biotin acceptor peptide tag (Cull and Schatz 2000; Schatz 1993). Final yeast surface density of bvDR4 was controlled by varying the

concentration of biotin in the initial yeast-labeling step, and presence and levels of the final immobilized protein on the yeast surface were assessed by flow cytometry (Figure 4). These yeast were tested for their ability to stimulate IL-2 production from HA1.7. While biotinylated bvDR4 immobilized on an avidin-coated tissue culture well yielded >1200 units/mL of IL-2, yeast samples failed to stimulate detectable IL-2 production (i.e., < 10 units/mL) by HA1.7 (data not shown). Controls using DR4-FLU-transfected fibroblasts as antigen presenting cells (Boen et al. 2000) yielded no detectable difference in IL-2 production by HA1.7 in the presence or absence of excess yeast (data not shown), confirming that yeast have no inhibitory effect on T cell function or the assay methods.

DISCUSSION

To date, yeast display of MHCII has been limited to two examples: murine I-A^{g7} (Starwalt et al. 2003) and human HLA-DR1 (Esteban and Zhao 2004). In both cases, display of native protein required isolation of mutants from combinatorial libraries and therefore raise questions regarding the potential impact of these mutations on peptide-binding kinetics or protein stability. Each of these examples made use of typical yeast display constructs with the Aga2p anchoring subunit N-terminal to a single-chain MHCII derivative (largely analogous to construct A in Figure 1). In this study, we have tested the ability of yeast to display an additional human MHCII, HLA-DR4, and we have assessed two fusion protein formats in which the Aga2p anchoring partner is linked to the N- and C-terminus of the DR4 β chain, respectively (Figure 1). The C-terminal Aga2p fusion (construct B) more closely mimics the anchoring mechanism of MHCII expressed on APC via transmembrane domains at the C-terminus of both the α and β chains. The data indicate that HLA-DR4 expresses well with a C-terminal Aga2p (construct B) but with an N-terminal Aga2p expresses at levels sufficiently low to preclude detection of DR4 β

by immunofluorescent staining (Figures 2 and 3A,B). These data are consistent with previous reports on yeast display of other MHCII (Starwalt et al. 2003; Esteban and Zhao 2004) but further indicate that successful display of wild-type MHCII on yeast is possible using the appropriate fusion protein system (construct B in Figure 1).

Staining with conformationally sensitive antibodies enables probing of DR4 conformational state and peptide loading (Figure 3). Our results indicate that yeast-displayed DR4 is native; furthermore, mAb L243 reportedly fails to react with isolated DR α chain (Horejsi et al. 1986), presumably because the MHCII α chain fails to fold natively in the absence of the β chain. Heat denaturation of the yeast quantitatively abrogates L243 binding, as expected for a noncovalently associated heterodimer. Thus, this work represents the first demonstration that yeast surface display is not limited to simple single-chain protein display or disulfide-bonded Fab display, but can also be used to successfully display complex noncovalent multimers. Monoclonal antibodies directed against a β chain epitope that is masked in native, peptide-loaded DR4 fail to react with DR4-displaying yeast, but demonstrate significant binding following heat denaturation, as shown in Figure 3C. These results strongly suggest that the yeast-displayed DR4 is functional in terms of peptide binding activity.

We were unable to demonstrate T cell receptor binding activity of our yeast-displayed protein; however, yeast coated with functional DR4 produced in insect cells likewise failed to demonstrate activity. Fluorescent tetramers of chimeric human/mouse HA1.7 TCR also failed to stain DR4-displaying yeast, but these reagents also failed to stain 75IP-DR4-FLU fibroblasts (which activate HA1.7 T cells) and thus this result is inconclusive (data not shown). BIAcore analysis of monomeric HA1.7 TCR binding to baculovirus-produced DR4-FLU suggests the affinity is low ($> 50 \mu\text{M}$; E.T. Boder, P.C. Marrack, J.W. Kappler, unpublished observations)

and thus insufficient for TCR tetramer binding, which occurs in the absence of avidity-enhancing CD4 binding.

Interestingly, 2.8 μm streptavidin-coated magnetic beads incubated with bvDR4 also failed to stimulate detectable IL-2 production from HA1.7 T cells (data not shown). Previous experiments have indicated that CD8+ cytotoxic T lymphocyte (CTL) activation by pMHC adsorbed to latex microspheres requires “cell sized” particles $\sim 5 \mu\text{m}$ diameter (Mescher 1992). Beads 1 - 2 μm in diameter yielded no CTL activity, while 5 μm beads stimulated a weak response. Valitutti and colleagues also showed a similar effect in a CD8 T cell system (Zaru et al. 2002). pMHC-coated polystyrene beads weakly stimulated antigen-specific T cells, but co-immobilization of anti-CD2 mAb potentiated T cell activation. Particles presenting a T cell contact surface with a small radius of curvature seem to yield nonproductive interaction despite the presence of cognate pMHC-TCR interaction.

Taken together with our data, these results suggest that geometry of the antigen-presenting particle may be important for both CD8 and CD4 T cell stimulation, at least by artificial antigen-presenting particles lacking co-stimulatory interactions. It is noteworthy that the antigen-presenting particles in the current study (yeast) and those discussed above (synthetic beads) present spatially restricted ligands incapable of two-dimensional diffusion on the surface of the particle; thus, supramolecular activation cluster (Monks et al. 1998) or immunological synapse (Bromley et al. 2001) formation is not possible in these systems regardless of the presence of costimulatory ligands. Although these spatial patterns have been suggested as important to both thymic selection and peripheral T cell activation *in vivo* (Jacobelli et al. 2004; Lee et al. 2003a; Lee et al. 2002; Minter and Osborne 2003), synapse formation is clearly not required for T cell stimulation in all cases. Nonetheless, it would be interesting to investigate the

effects of antigen presenting particle size on T cell stimulation in a system allowing ligand diffusion on the presenting particle, such as a lipid vesicle. This information might further corroborate physical models of the T cell-APC interaction in which T cell membrane bending modulus and thermal fluctuations play a critical role in spatial pattern formation, with apparent effects on signaling and activation (Lee et al. 2003b; Lee et al. 2002).

ACKNOWLEDGMENTS

This work was supported by the National Science Foundation under CAREER Award No. 0239099, the Merck Engineering Foundation, and the Howard Hughes Medical Institute. We thank the staff of the NJC Flow Cytometry Facility, the NJC Molecular Resources Facility, and the Penn Flow Cytometry and Cell Sorting Shared Resource for technical assistance.

Figure 1. Map of yeast display vector for expression of heterodimeric proteins. Two expression cassettes are driven by the bidirectional GAL1-10 promoter. Yeast Aga2p mediates surface linkage. Plasmid Z27 (Construct A) and plasmid Z47 (Construct B) differ with respect to Aga2p fusion at the N- and C-terminus of the peptide-DR4 β chain, respectively, and with respect to the orientation of the promoter; Z27: GAL1 = AGA2-DR4 β and GAL10 = DR α ; Z47: GAL1 = DR α and GAL10 = DR4 β -AGA2. DR α is solubly expressed and directed to the secretory pathway via a synthetic leader sequence. HA represents hemagglutinin epitope tag sequence YPYDVPDYA recognized by mAb 12CA5.

Figure 2. Flow cytometric analysis of Aga2p-FLU-DR4 expression on the yeast cell surface. Yeast transformed with Z27 (Construct A) were induced in galactose for 48 hr at 20°C and stained for expression of the HA epitope tag (mAb 12CA5), DR4 β chain (L227), and DR α chain (L243), as indicated. No 1° = control stained with secondary antibody only.

Figure 3. Analysis of peptide-loading of yeast-displayed HLA-DR4-FLU. (A-C) Yeast expressing DR4 (construct B) were incubated at room temperature (filled) or 80°C (empty) and immunofluorescently stained with mAbs against the (A) HA epitope tag, (B) DR α chain, and (C) DR β 58 - 69 epitope. (D) Control yeast expressing an unrelated protein were stained with protein specific mAb following room temperature incubation (filled) or KL295 (open, solid line) and irrelevant control mAb (open, dashed) following incubation at 80°C.

Figure 4. Levels of insect cell-produced HLA-DR4-FLU presented by yeast. Yeast expressing FLU-DR4-Aga2p were nonspecifically biotinylated with the indicated concentrations of NHS-

biotin prior to binding of avidin and site-specifically biotinylated HLA-DR4-FLU. Cells were stained with anti-DR α chain mAb LB3.1 and analyzed by flow cytometry.

REFERENCES

- Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM. 1996. Phenotypic analysis of antigen-specific T lymphocytes. *Science* 274(5284):94-6.
- Arimilli S, Astafieva I, Mukku PV, Cardoso C, Deshpande S, Nag B. 1999. Peptide binding inhibits aggregation of soluble MHC class II in solution. *IUBMB Life* 48(5):483-91.
- Arnold CE, Parekh RN, Yang W, Wittrup KD. 1998. Leader peptide efficiency correlates with signal recognition particle dependence in *Saccharomyces cerevisiae*. *Biotechnol Bioeng* 59(3):286-93.
- Boder ET, Wittrup KD. 2000. Yeast surface display for directed evolution of protein expression, affinity, and stability. *Methods Enzymol* 328:430-44.
- Boen E, Crownover AR, McIlhaney M, Korman AJ, Bill J. 2000. Identification of T cell ligands in a library of peptides covalently attached to HLA-DR4. *J Immunol* 165(4):2040-7.
- Bromley SK, Burack WR, Johnson KG, Somersalo K, Sims TN, Sumen C, Davis MM, Shaw AS, Allen PM, Dustin ML. 2001. The immunological synapse. *Annu Rev Immunol* 19:375-96.
- Brophy SE, Holler PD, Kranz DM. 2003. A yeast display system for engineering functional peptide-MHC complexes. *J Immunol Methods* 272(1-2):235-46.
- Chen W, Georgiou G. 2002. Cell-Surface display of heterologous proteins: From high-throughput screening to environmental applications. *Biotechnol Bioeng* 79(5):496-503.
- Chlewicki LK, Holler PD, Monti BC, Clutter MR, Kranz DM. 2005. High-affinity, peptide-specific T Cell receptors can be generated by mutations in CDR1, CDR2 or CDR3. *J Mol Biol* 346(1):223-39.

- Crawford F, Kozono H, White J, Marrack P, Kappler J. 1998. Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes. *Immunity* 8(6):675-82.
- Cull MG, Schatz PJ. 2000. Biotinylation of proteins in vivo and in vitro using small peptide tags. *Methods Enzymol* 326:430-40.
- Esteban O, Zhao H. 2004. Directed evolution of soluble single-chain human class II MHC molecules. *J Mol Biol* 340(1):81-95.
- Ge Q, Stone JD, Thompson MT, Cochran JR, Rushe M, Eisen HN, Chen J, Stern LJ. 2002. Soluble peptide-MHC monomers cause activation of CD8+ T cells through transfer of the peptide to T cell MHC molecules. *Proc Natl Acad Sci U S A* 99(21):13729-34.
- Germain RN, Rinker AG, Jr. 1993. Peptide binding inhibits protein aggregation of invariant-chain free class II dimers and promotes surface expression of occupied molecules. *Nature* 363(6431):725-8.
- Holler PD, Chlewicki LK, Kranz DM. 2003. TCRs with high affinity for foreign pMHC show self-reactivity. *Nat Immunol* 4(1):55-62.
- Holler PD, Holman PO, Shusta EV, O'Herrin S, Wittrup KD, Kranz DM. 2000. In vitro evolution of a T cell receptor with high affinity for peptide/MHC. *Proc Natl Acad Sci U S A* 97(10):5387-92.
- Hoogenboom HR. 2002. Overview of antibody phage-display technology and its applications. *Methods Mol Biol* 178:1-37.
- Horejsi V, Nemec M, Angelisova P, Kristofova H, Gorga JC, Hilgert I. 1986. Characterization of seven new monoclonal antibodies against human DR, DR + DP and DQ1 + DQ3 antigens. *Tissue Antigens* 28(5):288-97.

- Huan J, Subramanian S, Jones R, Rich C, Link J, Mooney J, Bourdette DN, Vandenbark AA, Burrows GG, Offner H. 2004. Monomeric recombinant TCR ligand reduces relapse rate and severity of experimental autoimmune encephalomyelitis in SJL/J mice through cytokine switch. *J Immunol* 172(7):4556-66.
- Jacobelli J, Andres PG, Boisvert J, Krummel MF. 2004. New views of the immunological synapse: variations in assembly and function. *Curr Opin Immunol* 16(3):345-52.
- Kappler JW, Skidmore B, White J, Marrack P. 1981. Antigen-inducible, H-2-restricted, interleukin-2-producing T cell hybridomas. Lack of independent antigen and H-2 recognition. *J Exp Med* 153(5):1198-214.
- Kieke MC, Shusta EV, Boder ET, Teyton L, Wittrup KD, Kranz DM. 1999. Selection of functional T cell receptor mutants from a yeast surface- display library. *Proc Natl Acad Sci U S A* 96(10):5651-6.
- Kotzin BL, Falta MT, Crawford F, Rosloniec EF, Bill J, Marrack P, Kappler J. 2000. Use of soluble peptide-DR4 tetramers to detect synovial T cells specific for cartilage antigens in patients with rheumatoid arthritis. *Proc Natl Acad Sci U S A* 97(1):291-6.
- Kozono H, White J, Clements J, Marrack P, Kappler J. 1994. Production of soluble MHC class II proteins with covalently bound single peptides. *Nature* 369(6476):151-4.
- Kurokawa MS, Ohoka S, Matsui T, Sekine T, Yamamoto K, Nishioka K, Kato T. 2002. Expression of MHC class I molecules together with antigenic peptides on filamentous phages. *Immunol Lett* 80(3):163-8.
- Lamb JR, Eckels DD, Lake P, Woody JN, Green N. 1982. Human T-cell clones recognize chemically synthesized peptides of influenza haemagglutinin. *Nature* 300(5887):66-9.

- LaPan KE, Klapper DG, Frelinger JA. 1992. Production and characterization of two new mouse monoclonal antibodies reactive with denatured mouse class II beta chains. *Hybridoma* 11(2):217-23.
- Le Doussal J, Piqueras B, Dogan I, Debre P, Gorochoy G. 2000. Phage display of peptide/major histocompatibility complex. *J Immunol Methods* 241(1-2):147-58.
- Lee KH, Dinner AR, Tu C, Campi G, Raychaudhuri S, Varma R, Sims TN, Burack WR, Wu H, Wang J and others. 2003a. The immunological synapse balances T cell receptor signaling and degradation. *Science* 302(5648):1218-22.
- Lee SJ, Hori Y, Chakraborty AK. 2003b. Low T cell receptor expression and thermal fluctuations contribute to formation of dynamic multifocal synapses in thymocytes. *Proc Natl Acad Sci U S A* 100(8):4383-8.
- Lee SJ, Hori Y, Groves JT, Dustin ML, Chakraborty AK. 2002. Correlation of a dynamic model for immunological synapse formation with effector functions: two pathways to synapse formation. *Trends Immunol* 23(10):492-9.
- Lin Y, Tsumuraya T, Wakabayashi T, Shiraga S, Fujii I, Kondo A, Ueda M. 2003. Display of a functional hetero-oligomeric catalytic antibody on the yeast cell surface. *Appl Microbiol Biotechnol* 62(2-3):226-32.
- Mescher MF. 1992. Surface contact requirements for activation of cytotoxic T lymphocytes. *J Immunol* 149(7):2402-5.
- Minter LM, Osborne BA. 2003. Cell death in the thymus--it's all a matter of contacts. *Semin Immunol* 15(3):135-44.
- Monks CR, Freiberg BA, Kupfer H, Sciaky N, Kupfer A. 1998. Three-dimensional segregation of supramolecular activation clusters in T cells. *Nature* 395(6697):82-6.

- Novak EJ, Liu AW, Gebe JA, Falk BA, Nepom GT, Koelle DM, Kwok WW. 2001. Tetramer-guided epitope mapping: rapid identification and characterization of immunodominant CD4+ T cell epitopes from complex antigens. *J Immunol* 166(11):6665-70.
- Pluckthun A, Schaffitzel C, Hanes J, Jermutus L. 2000. In vitro selection and evolution of proteins. *Adv Protein Chem* 55:367-403.
- Reijonen H, Kwok WW. 2003. Use of HLA class II tetramers in tracking antigen-specific T cells and mapping T-cell epitopes. *Methods* 29(3):282-288.
- Rotzschke O, Falk K, Mack J, Lau JM, Jung G, Strominger JL. 1999. Conformational variants of class II MHC/peptide complexes induced by N- and C-terminal extensions of minimal peptide epitopes. *Proc Natl Acad Sci U S A* 96(13):7445-50.
- Schatz PJ. 1993. Use of peptide libraries to map the substrate specificity of a peptide-modifying enzyme: a 13 residue consensus peptide specifies biotinylation in *Escherichia coli*. *Biotechnology (N Y)* 11(10):1138-43.
- Shen ZM, Wang L, Pike J, Jue CK, Zhao H, de Nobel H, Kurjan J, Lipke PN. 2001. Delineation of functional regions within the subunits of the *Saccharomyces cerevisiae* cell adhesion molecule a-agglutinin. *J Biol Chem* 276(19):15768-75.
- Shusta EV, Holler PD, Kieke MC, Kranz DM, Wittrup KD. 2000. Directed evolution of a stable scaffold for T-cell receptor engineering. *Nat Biotechnol* 18(7):754-9.
- Skinner PJ, Daniels MA, Schmidt CS, Jameson SC, Haase AT. 2000. Cutting Edge: In Situ Tetramer Staining of Antigen-Specific T Cells in Tissues. *J Immunol* 165(2):613-617.
- Starwalt SE, Masteller EL, Bluestone JA, Kranz DM. 2003. Directed evolution of a single-chain class II MHC product by yeast display. *Protein Eng* 16(2):147-56.

- Stern LJ, Wiley DC. 1994. Antigenic peptide binding by class I and class II histocompatibility proteins. *Structure* 2(4):245-51.
- van den Beucken T, Pieters H, Steukers M, van der Vaart M, Ladner RC, Hoogenboom HR, Hufton SE. 2003. Affinity maturation of Fab antibody fragments by fluorescent-activated cell sorting of yeast-displayed libraries. *FEBS Lett* 546(2-3):288-94.
- Vest Hansen N, Ostergaard Pedersen L, Stryhn A, Buus S. 2001. Phage display of peptide / major histocompatibility class I complexes. *Eur J Immunol* 31(1):32-8.
- Weaver-Feldhaus JM, Lou J, Coleman JR, Siegel RW, Marks JD, Feldhaus MJ. 2004. Yeast mating for combinatorial Fab library generation and surface display. *FEBS Lett* 564(1-2):24-34.
- Weidanz JA, Card KF, Edwards A, Perlstein E, Wong HC. 1998. Display of functional alphabeta single-chain T-cell receptor molecules on the surface of bacteriophage. *J Immunol Methods* 221(1-2):59-76.
- Wittrup KD. 2001. Protein engineering by cell-surface display. *Curr Opin Biotechnol* 12(4):395-9.
- Zaru R, Cameron TO, Stern LJ, Muller S, Valitutti S. 2002. Cutting edge: TCR engagement and triggering in the absence of large-scale molecular segregation at the T cell-APC contact site. *J Immunol* 168(9):4287-91.
- Zarutskie JA, Sato AK, Rushe MM, Chan IC, Lomakin A, Benedek GB, Stern LJ. 1999. A conformational change in the human major histocompatibility complex protein HLA-DR1 induced by peptide binding. *Biochemistry* 38(18):5878-87.

Figure 1
Boder, et al.

Figure 2
Boder, et al.

Figure 3
Boder, et al.

Figure 4
Boder, et al.